| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |